Related Experiment Video

Updated: Jul 1, 2026

Experimental Human Pneumococcal Carriage
07:47

Experimental Human Pneumococcal Carriage

Published on: February 15, 2013

Clinical and evidence-based considerations for choosing a pneumococcal conjugate vaccine in India: A narrative review

Vijay Yewale1, Pallab Chatterjee2, Sanjay M Marathe3

  • 1Department of Pediatrics, Apollo Children's Hospital, Navi Mumbai, India.

Human Vaccines & Immunotherapeutics
|April 3, 2025
PubMed

Insights

Pneumococcal conjugate vaccines (PCVs) are vital for preventing pneumococcal disease in children. This review examines evidence for evaluating PCV effectiveness and impact beyond initial immunogenicity studies.

Area of Science:

  • Pediatrics
  • Immunology
  • Public Health

Background:

  • Pneumococcal disease poses a significant public health challenge in India, despite being vaccine-preventable.
  • Pneumococcal conjugate vaccines (PCVs) have improved disease prevention, particularly in young children, by surpassing limitations of older polysaccharide vaccines.
  • Evaluating the real-world effectiveness and impact of new PCVs is crucial after their approval.

Purpose of the Study:

  • To consolidate evidence-based considerations for evaluating pneumococcal conjugate vaccines (PCVs).
  • To discuss critical aspects, importance, and limitations in assessing PCV performance in real-world settings.

Main Methods:

  • This review synthesizes existing literature and evidence on PCV evaluation.
  • It focuses on bridging immunogenicity data to vaccine efficacy and post-approval effectiveness.

Main Results:

  • Immunogenicity studies are currently used as a proxy for PCV approval.
  • Bridging immunogenicity results to vaccine efficacy requires robust post-approval effectiveness data.
  • Real-world data is essential for a comprehensive understanding of PCV impact.

Conclusions:

  • Establishing post-approval effectiveness and impact is critical for new PCVs.
  • A thorough evaluation of PCVs must consider real-world performance beyond initial immunogenicity.
  • This review provides a framework for evidence-based PCV assessment.

Keywords:
Immunitychildefficacypneumococcal diseasevaccine

More Related Videos

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria11:32

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

Opsono-Adherence Assay to Evaluate Functional Antibodies in Vaccine Development Against Bacillus anthracis and Other Encapsulated Pathogens13:47

Opsono-Adherence Assay to Evaluate Functional Antibodies in Vaccine Development Against Bacillus anthracis and Other Encapsulated Pathogens

Published on: May 19, 2020

Related Concept Videos

Vaccinations01:51

Vaccinations

Overview
43.1K
Acute Pharyngitis01:30

Acute Pharyngitis

Introduction
Acute pharyngitis is the inflammation of the back of the throat (pharynx), commonly resulting in a sore throat. It is a frequently encountered condition that prompts individuals to seek medical advice.
Classification
Acute pharyngitis can be categorized based on its underlying cause:
305
Pneumonia I: Introduction01:30

Pneumonia I: Introduction

Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
199
Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
131
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
276
Pneumonia V: Nursing management and Prevention01:30

Pneumonia V: Nursing management and Prevention

Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
1.7K